REVIEWStimulants and Acetylcholinesterase Inhibitors for the Treatment of Cognitive Impairment After Traumatic Brain InjuryArciniegas, David B. MD; Silver, Jonathan M. MD; McAllister, Thomas W. MDEditor(s): Janicak, Philip G. MD Author Information Dr. Arciniegas is Medical Director, Brain Injury Rehabilitation Unit, HealthONE Spalding Rehabilitation Hospital, Aurora, CO, Director, Neurobehavioral Disorders Program, and Associate Professor of Psychiatry and Nerology, University of Colorado, Denver, School of Medicine, Aurora, CO; Dr. Silver is Clinical Professor of Psychiatry, New York University School of Medicine, 40 E. 83rd St., New York, NY 10028, E-mail: [email protected]; and Dr. McAllister is Millennium Professor of Psychiatry and Director of Neuropsychiatry, Dartmouth Medical School, Lebanon, NH. The authors have disclosed that they have no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity. This work was supported in part by HealthONE Spalding Rehabilitation Hospital, the National Institutes of Health (grants RO1 NS40472-01, RO1 HD048176-01, RO1 NS055020, R01 HD48638), the New Hampshire Hospital, and the Ira DeCamp Foundation. The authors also have disclosed that no medications for treatment of neuropsychiatric consequences of traumatic brain injury as discussed in this article have been approved by the U.S. Food and Drug Administration. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Psychopharm Review 43(12):p 91-97, December 2008. | DOI: 10.1097/01.IDT.0000341722.37472.2d Buy CME Test Metrics © 2008 Lippincott Williams & Wilkins, Inc.